Calibrant, Yale to Collaborate on Ovarian, Breast Cancer Drug ID Study

Feb 07, 2008

NEW YORK (GenomeWeb News) – Calibrant Biosystems today said that it will collaborate with researchers at the Yale University School of Medicine to identify ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant’s Gemini proteomics platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH Boost Proposed

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Police, Genealogy, and Privacy

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

Gotta Sequence 'Em All

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

This Week in Science

In Science this week: environmental DNA can help in studies of marine animals, and more.

Main menu